9mo
Discussion Prompt: How have payor criteria shaped your timing of anti‑CGRP MAbs, and patient outcomes?
Share
9mo
Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38971750/
The contribution of chronic kidney disease (CKD) towards the risk of developing cardiovascular disease (CVD) is magnified with co-existing type 1 or type 2 diabetes. Lipids are a modifiable risk...
This guideline provides practical recommendations on lipid management to reduce cardiovascular risk in adults with diabetic kidney disease, aiming to improve outcomes through multidisciplinary care for CKD and diabetes.
Share
9mo
Effects of Cocoa Consumption on Cardiometabolic Risk Markers: Meta-Analysis of Randomized Controlled Trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38931273/
The consumption of cocoa showed protective effects on major cardiometabolic risk markers that have a clinical impact in terms of cardiovascular risk reduction.
Cocoa consumption modestly improves LDL-c, total cholesterol, fasting glucose, and blood pressure in adults, but shows no impact on weight, BMI, waist circumference, triglycerides, HDL-c, or HbA1c.
Share
9mo
Intravenous Lipid Emulsion for Managing Local Anesthetic Toxicity in a Three-Month-Old Patient - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39830580/
Local anesthetic systemic toxicity (LAST) is a well-known life-threatening local anesthetics complication, especially if given in inappropriate doses or routes. Therefore, physicians should be aware of LAST symptoms, such as...
A three-month-old infant developed cardiac symptoms from LAST after a caudal block; early intravenous lipid emulsion treatment effectively reversed symptoms, restoring normal vitals without complications.
Share
9mo
ORION‑3 shows 44 % LDL‑C reduction sustained over 4 yrs with 6‑monthly dosing; pooled ORION‑9/10/11 hint at MACE drop. No safety signal beyond mild injection‑site reactions.
Could siRNA free patients from statin fatigue?
Share